Trials / Unknown
UnknownNCT02158299
Contrast The Role of Avitene And OK-432 in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer
Contrast The Role of Microfibrillar Collagen Hemostat Flour(Avitene) And OK-432 (Sapylin)in Reducing Seroma Formation After Axillary Lymphadenectomy for Breast Cancer
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 3 (estimated)
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
After Axillary lymphadenectomy for breast cancer there are not few patients showed seroma formation and it can not be ignored.Investigators aimed to study two new methods of application of Microfibrillar Collagen Hemostat Flour and OK-432 to reduce seroma formation and to verify the efficacy and safety of these two applications.Try to prove them as beneficial supplements for axillary lymphadenectomy of breast cancer.
Detailed description
A prospective,randomized analysis of breast-conserving surgery or mastectomy plus axillary lymphadenectomy for those patients with sentinel node positive using Microfibrillar Collagen Hemostat Flour 、 OK-432 or using nothing in equal probability.Up to 12 months,a total of 180 will be recruited in plan.During the operation and after the axillary lymphadenectomy,according the arms,Investigators put Microfibrillar Collagen Hemostat Flour(avitene)、 OK-432(Sapylin) or nothing into patients axillary wounds。And Investigators will the statistical significance of these three arms that the postoperative drainage magnitude and duration.Also the complications associated with axillary lymphadenectomy will be studied.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avitene | |
| DRUG | Sapylin | |
| BEHAVIORAL | axillary drainage | |
| OTHER | reexamine |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2014-11-01
- First posted
- 2014-06-06
- Last updated
- 2014-06-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02158299. Inclusion in this directory is not an endorsement.